FDA acceptance for review of AVT80 BLA is a major pipeline milestone that signals progressing regulatory confidence and de-risks the Entyvio biosimilar program. Traders should watch for the PDUFA target action date (typically 10-12 months from filing) and any FDA Advisory Committee meeting announcements as near-term catalysts. Monitor Alvotech's partnerships with Teva for commercialization updates, and any competitive developments from other biosimilar developers (e.g., Celltrion, Pfizer).
Price Chart
Executive Summary
Alvotech announced FDA acceptance for review of its BLA for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) in subcutaneous presentations (prefilled syringe and autoinjector). This follows the May 2026 acceptance of AVT16 (IV formulation) and completes the company's Entyvio biosimilar program covering both routes of administration. Teva will commercialize AVT80 in the U.S. under an existing partnership.
Key Facts
- FDA accepted for review a BLA for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) for subcutaneous administration via prefilled syringe and autoinjector
- AVT80 complements AVT16 (IV formulation), which had its BLA accepted for review in May 2026
- Teva is responsible for commercialization in the U.S. under an existing partnership
- AVT80 is supported by a pivotal pharmacokinetic study that met all primary endpoints (announced February 2026)
- In the EU, the EMA has validated a Marketing Authorization Application covering both AVT16 and AVT80
- Alvotech has five biosimilars already approved and marketed globally in multiple markets
Financial Impact
Entry into the $1.6B+ U.S. Entyvio market (subcutaneous) represents a significant revenue opportunity; no specific financial guidance or deal values provided in the filing
Risk Factors
- Regulatory approval is not guaranteed; AVT80 remains an investigational product and biosimilarity/interchangeability has not been established
- Entyvio (vedolizumab) patent litigation and regulatory exclusivity could delay or block market entry
- Commercial uptake depends on interchangeability designation and payer coverage decisions
- Competition from other biosimilar candidates targeting Entyvio (e.g., from Celltrion, Mylan/Viatris)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005793 |
| Document: f6k_083126.htm | 0001171843-26-005793 |
| Document: 0001171843-26-005793-index-headers.html | 0001171843-26-005793 |
| Document: 0001171843-26-005793-index.html | 0001171843-26-005793 |
| Document: 0001171843-26-005793.txt | 0001171843-26-005793 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $5.12 | awaiting T+20 | — | $4.73 (−7.62%) |
Oct 14, 2026 13d ago | 6-K | $5.17 | awaiting T+20 | — | $4.73 (−8.51%) |
Oct 7, 2026 20d ago | 6-K | $5.85 | awaiting T+20 | — | $4.73 (−19.15%) |
Oct 5, 2026 22d ago | 6-K | $6.11 | awaiting T+20 | — | $4.73 (−22.59%) |
Oct 5, 2026 22d ago | Press Release | $6.11 | awaiting T+20 | — | $4.73 (−22.59%) |
Aug 31, 2026 8w ago | 6-K | $5.19 $5.92 | ▲ +14.07% | ▲ +14.44% | $4.73 (−8.86%) |
Aug 21, 2026 9w ago | 6-K | $4.43 $5.88 | ▲ +32.73% | ▲ +31.72% | $4.73 (+6.77%) |
Aug 19, 2026 9w ago | Press Release | $4.27 $5.87 | ▼ −37.47% | ▼ −37.59% | $4.73 (−10.77%) |
Jul 29, 2026 12w ago | 6-K | $3.53 $4.91 | ▲ +39.09% | ▲ +34.07% | $4.73 (+33.99%) |
Jul 3, 2026 16w ago | Press Release | $3.46 $4.12 | ▲ +19.08% | ▲ +19.64% | $4.73 (+36.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers